The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The
https://
ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
the contents by NLM or the National Institutes of Health.
Learn more:
PMC Disclaimer
Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study.
PLoS One
2015;
10
:e0143515. 10.1371/journal.pone.0143515
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
2.
Gelatti ACZ, Drilon A, Santini FC.
Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Lung Cancer
2019;
137
:113-22. 10.1016/j.lungcan.2019.09.017
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
3.
Zhou J, Mo W, Zhao J, et al.
Clinicopathological features associated with EGFR gene mutation in non-small cell lung cancer patients.
Zhonghua Yi Xue Za Zhi
2014;
94
:2332-6. [
PubMed
]
[
Google Scholar
]
4.
Li Z, Zhang LJ, Wang WP, et al.
Correlation between EGFR gene mutation and high copy number and their association with the clinicopathological features in Chinese patients with non-small cell lung cancer.
Zhonghua Zhong Liu Za Zhi
2011;
33
:666-70. [
PubMed
]
[
Google Scholar
]
5.
Pi C, Xu CR, Zhang MF, et al.
EGFR mutations in early-stage and advanced-stage lung adenocarcinoma: Analysis based on large-scale data from China.
Thorac Cancer
2018;
9
:814-9. 10.1111/1759-7714.12651
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
6.
Castellanos E, Feld E, Horn L.
Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non-Small Cell Lung Cancer.
J Thorac Oncol
2017;
12
:612-23. 10.1016/j.jtho.2016.12.014 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
7.
Scaltriti M, Baselga J.
The epidermal growth factor receptor pathway: a model for targeted therapy.
Clin Cancer Res
2006;
12
:5268-72. 10.1158/1078-0432.CCR-05-1554 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
8.
Mok TS, Wu YL, Thongprasert S, et al.
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
N Engl J Med
2009;
361
:947-57. 10.1056/NEJMoa0810699 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
9.
Baek JH, Sun JM, Min YJ, et al.
Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: a retrospective analysis in Korea.
Lung Cancer
2015;
87
:148-54. 10.1016/j.lungcan.2014.11.013 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
10.
Yoneda K, Imanishi N, Ichiki Y, et al.
Treatment of Non-small Cell Lung Cancer with EGFR-mutations.
J UOEH
2019;
41
:153-63. 10.7888/juoeh.41.153 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
11.
Wu SG, Shih JY.
Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer.
Mol Cancer
2018;
17
:38. 10.1186/s12943-018-0777-1
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
12.
Guo Y, Song J, Wang Y, et al.
Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review.
Front Oncol
2020;
10
:610923. 10.3389/fonc.2020.610923
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
13.
Kashima K, Kawauchi H, Tanimura H, et al.
CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation.
Mol Cancer Ther
2020;
19
:2288-97. 10.1158/1535-7163.MCT-20-0229 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
14.
Remon J, Steuer CE, Ramalingam SS, et al.
Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients.
Ann Oncol
2018;
29
:i20-7. 10.1093/annonc/mdx704 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
15.
Goss G, Tsai CM, Shepherd FA, et al.
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.
Lancet Oncol
2016;
17
:1643-52. 10.1016/S1470-2045(16)30508-3 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
16.
Yang JC, Ahn MJ, Kim DW, et al.
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.
J Clin Oncol
2017;
35
:1288-96. 10.1200/JCO.2016.70.3223 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
17.
Mu Y, Hao X, Xing P, et al.
Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
J Cancer Res Clin Oncol
2020;
146
:2427-33. 10.1007/s00432-020-03239-1
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
18.
Wang F, Diao XY, Zhang X, et al.
Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations.
Cancer Commun (Lond)
2019;
39
:7. 10.1186/s40880-019-0354-z
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
19.
Oxnard GR, Hu Y, Mileham KF, et al.
Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib.
JAMA Oncol
2018;
4
:1527-34. 10.1001/jamaoncol.2018.2969
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
20.
Thress KS, Paweletz CP, Felip E, et al.
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.
Nat Med
2015;
21
:560-2. 10.1038/nm.3854
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
21.
Uchibori K, Inase N, Araki M, et al.
Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer.
Nat Commun
2017;
8
:14768. 10.1038/ncomms14768
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
22.
Yaeger R, Kotani D, Mondaca S, et al.
Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer.
Clin Cancer Res
2019;
25
:7089-97. 10.1158/1078-0432.CCR-19-2004
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
23.
Wang Y, Yang N, Zhang Y, et al.
Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination Therapy.
J Thorac Oncol
2020;
15
:1369-75. 10.1016/j.jtho.2020.04.014 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
24.
Heigener DF, Reck M.
Crizotinib.
Recent Results Cancer Res
2018;
211
:57-65. 10.1007/978-3-319-91442-8_4 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
25.
Li Y, Su S, Cai G, et al.
Responses to crizotinib and chemotherapy in patients with lung adenocarcinoma harboring a concomitant EGFR mutation and ALK gene rearrangement: A case report and review of the literature.
Mol Clin Oncol
2017;
7
:173-82. 10.3892/mco.2017.1306
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
26.
Kim M, Mun H, Sung CO, et al.
Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening.
Nat Commun
2019;
10
:3991. 10.1038/s41467-019-11867-6
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
27.
van Veggel B, de Langen AJ, Hashemi S, et al.
Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.
Lung Cancer
2018;
124
:130-4. 10.1016/j.lungcan.2018.07.030 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
28.
Wang Y, Tian P, Xia L, et al.
The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy.
Lung Cancer
2020;
146
:165-73. 10.1016/j.lungcan.2020.06.003 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
29.
Shi YK, Fang J, Zhang S, et al.
Safety and efficacy of WX-0593 in ALK-positive or ROS1-positive non-small cell lung cancer.
Ann Oncol
2019;
30
:v607-v608. 10.1093/annonc/mdz260.007 [
CrossRef
]
[
Google Scholar
]
30.
Liu X, Zhang L, Wan H, et al.
Discovery and preclinical evaluations of WX-0593, a novel ALK inhibitor targeting crizotinib-resistant mutations.
Bioorg Med Chem Lett
2022;
66
:128730. 10.1016/j.bmcl.2022.128730 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
31.
Jia Y, Yun CH, Park E, et al.
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.
Nature
2016;
534
:129-32. 10.1038/nature17960
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
32.
Zhou Z, Zhao Y, Shen S, et al.
Durable Clinical Response of Lung Adenocarcinoma Harboring EGFR 19Del/T790M/in trans-C797S to Combination Therapy of First- and Third-Generation EGFR Tyrosine Kinase Inhibitors.
J Thorac Oncol
2019;
14
:e157-9. 10.1016/j.jtho.2019.04.020 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
33.
To C, Jang J, Chen T, et al.
Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor.
Cancer Discov
2019;
9
:926-43. 10.1158/2159-8290.CD-18-0903
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
34.
Li Q, Zhang T, Li S, et al.
Discovery of Potent and Noncovalent Reversible EGFR Kinase Inhibitors of EGFRL858R/T790M/C797S.
ACS Med Chem Lett
2019;
10
:869-73. 10.1021/acsmedchemlett.8b00564
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
35.
Mazzarella L, Guida A, Curigliano G.
Cetuximab for treating non-small cell lung cancer.
Expert Opin Biol Ther
2018;
18
:483-93. 10.1080/14712598.2018.1452906 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
36.
Wang Y, Wang H, Jiang Y, et al.
A randomized phase III study of combining erlotinib with bevacizumab and panitumumab versus erlotinib alone as second-line therapy for Chinese patients with non-small-cell lung cancer.
Biomed Pharmacother
2017;
89
:875-9. 10.1016/j.biopha.2017.02.097 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
37.
Vlahovic G, Meadows KL, Hatch AJ, et al.
A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer.
Oncologist
2018;
23
:782-90. 10.1634/theoncologist.2016-0377
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
38.
Wang Y, Ma X, Wei Y, et al.
Effect of platinum-based chemotherapy on EGFR gene mutation status in lung adenocarcinoma.
Medicine (Baltimore)
2018;
97
:e9602. 10.1097/MD.0000000000009602
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
39.
Zhao Y, Liu J, Cai X, et al.
Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis.
2019;
367
:l5460. 10.1136/bmj.l5460
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
40.
Yun J, Lee SH, Kim SY, et al.
Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC.
Cancer Discov
2020;
10
:1194-209. 10.1158/2159-8290.CD-20-0116 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
41.
Hoyle M, Crathorne L, Peters J, et al.
The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.
Health Technol Assess
2013;
17
:1-237. 10.3310/hta17140
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
42.
Wang X, Zhou L, Yin JC, et al.
Lung Adenocarcinoma Harboring EGFR 19del/C797S/T790M Triple Mutations Responds to Brigatinib and Anti-EGFR Antibody Combination Therapy.
J Thorac Oncol
2019;
14
:e85-8. 10.1016/j.jtho.2019.01.015 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
43.
Xile L, Ding CZ, Mao W, et al.
Abstract 4794: Preclinical evaluation of WX-0593, a potent orally active ALK inhibitor.
Cancer Res
2018;
78
:4794. 10.1158/1538-7445.AM2018-4794 [
CrossRef
]
[
Google Scholar
]
44.
Toshimoto K, Tomoda Y, Chiba K, et al.
Analysis of the Change in the Blood Concentration-Time Profile Caused by Complex Drug-Drug Interactions in the Liver Considering the Enterohepatic Circulation: Examining Whether the Inhibition Constants for Uptake, Metabolism, and Biliary Excretion Can be Recovered by the Analyses Using Physiologically Based Pharmacokinetic Modeling.
J Pharm Sci
2017;
106
:2727-38. 10.1016/j.xphs.2017.04.057 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
45.
Kumai T, Oikawa K, Aoki N, et al.
Assessment of the change in cetuximab-induced antibody-dependent cellular cytotoxicity activity of natural killer cells by steroid.
Head Neck
2016;
38
:410-6. 10.1002/hed.23906 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
46.
Funakoshi T, Suzuki M, Tamura K.
Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab: a systematic review and meta-analysis.
Cancer Treat Rev
2014;
40
:1221-9. 10.1016/j.ctrv.2014.09.002 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
48.
Zhang ZH, Han YW, Liang H, et al.
Prognostic value of serum CYFRA21-1 and CEA for non-small-cell lung cancer.
Cancer Med
2015;
4
:1633-8. 10.1002/cam4.493
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
49.
Ma R, Xu H, Wu J, et al.
Identification of serum proteins and multivariate models for diagnosis and therapeutic monitoring of lung cancer.
Oncotarget
2017;
8
:18901-13. 10.18632/oncotarget.14782
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
Articles from
Annals of Translational Medicine
are provided here courtesy of
AME Publications
